港股異動丨百濟神州(6160.HK)高開約4% 百悦澤®在澳大利亞取得首次批准用於治療華氏巨球蛋白血癥
格隆匯10月8日丨百濟神州(6160.HK)高開約4%,報216港元,總市值2621億港元。百濟神州今早宣佈旗下產品百悦澤®(澤布替尼)在澳大利亞獲批用於治療既往接受過至少一種療法的華氏巨球蛋白血癥(WM)成人患者,或作為一線療法以用於治療不適合化學免疫治療的患者。在百悦澤®獲得澳大利亞藥品管理局(TGA)批准之後,通過百濟神州贊助的患者援助計劃,患者可以在百悦澤®雖已獲批但尚未納入醫保的情況下即刻獲得藥品。此外,百悦澤®近期也已獲得新加坡衞生科學局(HSA)批准,用於治療既往接受過至少一種治療的套細胞淋巴瘤(MCL)成人患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.